Market Overview

Sarcopenia Therapeutics 2018: Pipeline Analysis, Clinical Trials & Results, Patents, Designations and Collaborations - ResearchAndMarkets.com

Share:

The "Sarcopenia
Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results,
Patents, Designations, Collaborations, and Other Developments"

report has been added to ResearchAndMarkets.com's
offering.

The study analyzed that the sarcopenia therapeutics pipeline comprises
of 13 drug candidates in different stages of development. Further, the
analysis also states that the pipeline has around 15% of the drug
candidates that are being developed as gene therapy.

Novartis AG, and Regeneron Pharmaceuticals Inc., have one drug candidate
each in the Phase II stage of development for the treatment of the
disease. In December 2017, Biophytis SAS announced that the Federal
Agency for Medicines and Health Products (FAMHP) approved to conduct the
SARA-INT Phase II interventional study of sarcopenia in Belgium.

The drugs being developed by the various pharmaceutical companies for
the treatment of sarcopenia have demonstrated positive clinical trial
results which in-turn aids in their further development. For instance,
In June 2017, Novartis AG announced the positive results of a 24-week
randomized, double-blind, placebo-controlled, parallel-arm,
proof-of-concept study of bimagrumab on skeletal muscle mass and
function in older adults with sarcopenia and mobility limitations. In
February 2016, ATA 842 demonstrated increased muscle mass and muscle
strength in the treatment of young and old mice in four weeks.

It has been observed that most of the drug candidates have received or
have filed for patent covering a novel mechanism for the treatment of
sarcopenia. For instance, in June 2016, Novartis AG received patent for
the invention related to myostatin or activin antagonists, dose regimen
and pharmaceutical compositions thereof, for the treatment of
age-related sarcopenia (WO2015IB59369 20151204). Patent approval helps
in increasing opportunities for invention improvement and uniqueness for
the pharmaceutical companies.

Key Players

  • Novartis AG
  • Biophytis SAS
  • Vibe Pharmaceuticals LLC

Other Notable Players

  • Neurotune AG

Key Topics Covered

1. Research Background

2. Research Methodology

3. Executive Summary

4. Pipeline Outlook

5. Sarcopenia Therapeutics Pipeline Analysis by Phase (2018)

6. Clinical Trials Review

7. Competitive Landscape

8. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/b255lb/sarcopenia?w=4

View Comments and Join the Discussion!